Atrial fibrillation and isolated systolic hypertension the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study

Hypertension

Volumn 51, Issue 6, 2008, Pages 1552-1556

  Vagaonescu, Tudor D ^a   Wilson, Alan C ^a   Kostis, John B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Atenolol; Atrial fibrillation; Chlorthalidone; Death; Elderly; Hypertension; Incidence

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CHLORTALIDONE; DIGOXIN; PLACEBO; RESERPINE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SUDDEN DEATH; SYSTOLIC HYPERTENSION; AGING; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL FIBRILLATION; BLOOD PRESSURE; CAUSE OF DEATH; CHLORTHALIDONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 45849132016     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.110775     Document Type: Article

References (18)

1. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285:2370-2375.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
3. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ. Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Study. JAMA. 1994; 271:840844.
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
5. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96: 2455-2461.
6. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154: 1449-1457.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA, 1991;265:3255-3264.
8. Borhani NO, Appiegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield JL. Systolic Hypertension in the Elderly Program (SHEP). Part 1: rationale and design. Hypertension. 1991 ; 17:112-1115.
9. Kostis JB, Prineas R, Curb JD, Lee M, Berkson D, Raines J, Frishman W, Francis CK, Sheffield T. Systolic Hypertension in the Elderly Program (SHEP). Part 8: electrocardiographic characteristics. Hypertension, 1991; 17:II123-II151.
10. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34: 187-220.
11. Kitchin AH, Milne JS. Longitudinal survey of ischaemic heart disease in randomly selected sample of older population. Br Heart J. 1977 ;39: 889-893.
12. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995;98:476-484.
13. Lake FR, Cullen KJ, de Klerk NH, McCaIl MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust NZ J Med. 1989; 19:321-326.
14. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. Circulation. I998;98: 946-952.
15. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987;1:526-529.
16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-988.
17. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drag treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216.
18. Wachtell K, Lento M, Gerdts E, Olsen MH. Hornestam B. Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared with atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719.